Skip to content
★ Sign in to follow
3B BlackBio Dx logo

3B BlackBio Dx Stock: price and insider trades · India

IN·Mcap ₹13.1B

No insider purchase over the last 90 days. The latest, by Dhirendra Dubey, was filed 14 Jul 2026.

3B BlackBio Dx: what insiders have been doing

This page follows insider dealings at 3B BlackBio Dx as filed with SEBI (PIT + SAST). 2 insiders have disclosed 2 filings since 8 November 2025.

The flow runs one way only: 2 insiders bought (2 purchases totalling €11k) and nobody sold on the market. No amount is published for 1 filing, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 1 major shareholder and 1 senior executive. The largest single trade was a purchase of €11k by Dhirendra Dubey, published on 25 June 2026.

For context, the typical company on the same exchange (median of 1,985 companies) published 4 filings over the same period, against 2 filings here. Our records for 3B BlackBio Dx go back to 2026, with 2 purchases and no sales on the open market in total.

The latest purchase dates back some time: it was published 117 days ago, on 14 July 2026.

Every figure here comes from the filings published by SEBI (PIT + SAST) and describes the past, not future prices; it is not investment advice.

Insider Decl.
2
Thresholds
n/a
Buy Volume
€10,865
2 ops. · all time
Sell Volume
n/a
n/a

Who traded when

BuySale
Dhirendra Dubey2 buys

Since the insiders bought

  • Filed 14 Jul 2026 · 117 days ago
    -7.7%
    Entry ₹1,251.75 · Close at T+30 ₹1,155.26
  • Filed 25 Jun 2026 · 136 days ago · €11k
    +21.3%
    Entry ₹1,173.05 · Close at T+90 ₹1,422.68

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 3,478 of 26,897 companies
71.8
score / 100
Value
52
Quality
91
FCF yld2.4%
Earn yld5.4%
EV/EBITDA13.5x
ROE20%
Gross mgn75%
Net mgn42%
Debt/EBITDA0.1x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2026

FY ended March 2026 · cache

₹1,523.05
Analyst consensus
·
Income statement
Revenue₹1.4B
Gross profit₹1.1B75% margin
EBITDA₹823.3M58% margin
Net income₹599.3M36.3% margin
Valuation
PER (trailing)23.1x
P/Book3.9x
Beta0.38
Balance sheet & cash
Market cap₹13.1B
Total debt₹47.7M
Free Cash Flow₹269.7M
Debt / Equity1%
Profitability & ownership
ROE19.9%
ROA9.9%
% insiders63.9%
% institutions1.9%
Last declaration on 14 July 2026
Declarations2 total
  • ▲
    PromoterExecutives
    0SEBI
    1,000 shares-MarketSEBI:2f697d1214ee3dd155d65ebb741ed50c5b2d2432
    Canonical exit: 12 Oct 2026 (T+90)
  • ▲
    Promoter & DirectorExecutives
    1M INR19SEBI
    1,000 shares@ ₹1,166.00100.0% of flowEquity SharesMarket PurchaseSEBI:3fa55d4201ff069b7e8a3afc2a44039d512fd6a9
    Canonical exit: 23 Sept 2026 (T+90)

2 of 2 declarations

About 3B BlackBio Dx

3B BlackBio Dx is a company focused on developing innovative diagnostic solutions. It operates in the XBOM market.